氟达拉滨和环磷酰胺联合利妥昔单抗治疗慢性淋巴细胞白血病疗效分析

摘要

Objective Discussion fludarabine and cyclophosphamide , rituximab treatment of chronic lymphocytic leukemia effect, provide the basis for clinical treatment. Methods Selected 106 patients with chronic lymphocytic leukemia, were randomly divided into a control group and the treatment group , 53 patients in the control group fludarabine and cyclophosphamide treatment group fludarabine and cyclophosphamide combined with rituximab anti- therapy treatment , efficacy comparison observation.Results:CR 30 cases treatment group (56.60%), PR 16 cases (30.19%), NR 7 cases (13.21%), the total effective rate (CR + PR) 86.79%. CR 23 cases control group (43.40%), PR 17 cases (32.08%), NR 13 cases(24.53%), the total effective rate (CR + PR) 75.47%. Com-pare two sets of data, the total efficiency (CR + PR) chi-square test, χ2= 3.235, P = 0.045, * P <0.05, explain differences were statistically significant. Adverse results : the treatment group of bone marrow suppression in 15 cases (28.30%), liver toxicity in 8 cases(15.09%), gastrointestinal system, 6 cases (11.32%), the overall incidence of 54.72%. Myelosuppression 22 cases in the con-trol group (41.50%), 12 cases of liver toxicity (22.64%), 12 cases of digestive system (22.64%), the overall incidence of 86.79%. Compare two sets of data, the overall incidence of chi-square test , χ2=4.255, P = 0.034, * P <0.05, explain differences were sta-tistically significant. Conclusion Fludarabine and cyclophosphamide , rituximab treatment of chronic lymphocytic leukemia, not only can improve the therapeutic effect and reduce side effects, and can improve and enhance the quality of life of patients and re-duce the relapse rate , worthy of clinical application .%目的：探讨氟达拉滨和环磷酰胺联合利妥昔单抗治疗慢性淋巴细胞白血病疗效，为临床治疗提供依据。方法选取慢性淋巴细胞白血病患者106例，随机分为对照组和治疗组各53例，对照组应用氟达拉滨和环磷酰胺治疗，治疗组应用氟达拉滨和环磷酰胺联合利妥昔单抗治疗治疗，进行疗效比较观察。结果治疗组 CR 30例(56.60%)，PR 16例(30.19%)，NR 7例(13.21%)，总有效率(CR+PR)86.79%。对照组 CR 23例(43.40%)，PR 17例(32.08%)，NR 13例(24.53%)，总有效率(CR+PR)75.47%。两组数据比较，总有效率(CR+PR)卡方检验，χ2为3.235，P=0.045，*P＜0.05，差异有统计学意义。不良反应结果：治疗组骨髓抑制15例(28.30%)，肝脏毒性8例(15.09%)，消化道系统6例(11.32%)，总发生率54.72%。对照组骨髓抑制22例(41.50%)，肝脏毒性12例(22.64%)，消化道系统12例(22.64%)，总发生率86.79%。两组数据比较，总发生率卡方检验，χ2为4.255，P=0.034，*P＜0.05，差异有统计学意义。结论应用氟达拉滨和环磷酰胺联合利妥昔单抗治疗慢性淋巴细胞白血病，不仅可以提高治疗效果，减少不良反应，而且可以改善和提高患者的生活质量，降低复发率，值得临床推广应用。